Adaptive Biotechnologies Corp vs VanEck Gold Miners ETF — how do they compare? Adaptive Biotechnologies Corp trades at $24.9 (market cap $4.04B), while VanEck Gold Miners ETF trades at $91.34. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | GDX | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | — |
52-Week High | $25.45 | $115.84 |
52-Week Low | $12.30 | $56.60 |
Enterprise Value | $4.10B | — |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
GDX trades at $90.92, up 0.48% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights institutional repositioning and strong gold price momentum driving miner performance. The ETF offers diversified exposure to gold mining equities, though key valuation ratios are not publicly detailed for the fund itself.
The outlook is supported by gold's rally and potential for miner catch-up, but risks include gold price volatility and sector underperformance relative to bullion. Analyst sentiment is mixed, with some seeing value in miners after recent gains, while technical indicators warn of near-term overextension.
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →